Drug interactions
Buprenorphine transdermal + Lapatinib
Severity: Moderate
Buprenorphine transdermal and Lapatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lapatinib and transdermal buprenorphine can each prolong the QT interval, so together they may increase the chance of torsades de pointes. Transdermal buprenorphine labeling includes a QT warning, and the risk rises at higher doses.
What this interaction means in plain words
Buprenorphine transdermal and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Obtain a baseline and follow-up ECG and correct electrolyte abnormalities. Use the lowest effective buprenorphine dose, or choose a non-QT-prolonging opioid if the QTc lengthens.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine transdermal and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Frequently asked questions
Can I take Buprenorphine transdermal with Lapatinib?
MediHelp rates the interaction as moderate. Buprenorphine transdermal and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lapatinib and transdermal buprenorphine can each prolong the QT interval, so together they may increase the chance of torsades de pointes. Transdermal buprenorphine labeling includes a QT warning, and the risk rises at higher doses.
How serious is the interaction between Buprenorphine transdermal and Lapatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline and follow-up ECG and correct electrolyte abnormalities. Use the lowest effective buprenorphine dose, or choose a non-QT-prolonging opioid if the QTc lengthens.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
